Anixa Biosciences Inc
AI Executive Summary
AI-powered analysis of 10-Q filing content
Anixa Biosciences shows concerning financial deterioration with declining cash position, no revenue generation, and ongoing operating losses. The company continues burning cash at approximately $10.7M annually with only $13.7M in liquid assets remaining, suggesting potential funding challenges within 15 months.
Red Flags Detected (5)
Zero revenue despite R&D spending
Cash and short-term investments declined from $15.2M to $13.7M in 6 months
Accumulated deficit increased to $256.8M
2 more red flags detected
Key Takeaways
Pre-revenue biotech with significant cash burn
Approximately 15 months of runway remaining at current burn rate
2 more takeaways
Filing Overview
What This Means
High Risk Filing: This company is showing signs of financial stress or significant operational challenges.
Deteriorating Trend: Conditions are worsening compared to previous filings. This may create opportunities for service providers.
Quarterly Report: Interim filing with unaudited financial data for the quarter.